Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
RITTER PHARMACEUTICALS (RTTR)
Last ritter pharmaceuticals earnings: 8/14 05:11 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ritterpharmaceuticals.com/investors
Company Research
Source: GlobeNewswire
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that the first patient has been enrolled in the first pivotal Phase 3 clinical trial of RP-G28. “The initiation of this Phase 3 clinical trial for RP-G28, called the “Liberatus” study, is an important milestone not only for the company, but potentially for the way lactose intolerance is treated,” said Andrew J. Ritter, co-founder and president of Ritter Pharmaceuticals, Inc. “To date, there are no prescription drugs available to treat this condition, and we believe that our approach of modulating the microbiom
Show less
Read more
Impact Snapshot
Event Time:
RTTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RTTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RTTR alerts
High impacting RITTER PHARMACEUTICALS news events
Weekly update
A roundup of the hottest topics